Amarillo Biosciences Inc. (AMAR) insider have most recently took part in a trading activity. On Aug 24, 2017 Chen Stephen T, President, CEO & Chairman, 10% Owner bought 2,739 shares having total worth of $740 at the price of $0.27 per share, following the transaction a total of 3,852,696 shares owned by Chen Stephen T. Before this latest buy, Chen Stephen T purchased AMAR at 38 other times during the past twelve months, for a total investment of $117,529 at an average of $0.25 per share.
The stock has experienced a total of 15 insider trades in the past three months. These trades include 15 buy trades. Furthermore, over the past 12 months , the stock was traded 38 times by insiders. an employee of the company was the buyer in 38 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Amarillo Biosciences Inc. (AMAR) traded down 3.33% on Aug 24, 2017, hitting $0.26. 3,261 shares of the company’s stock traded hands. Amarillo Biosciences Inc. has a 52 week low of $0.05 and a 52 week high of $0.65. The company’s market cap is $0 million.
Amarillo Biosciences, Inc. is a Texas corporation formed in 1984. The Company is engaged in developing biologics for the treatment of human and animal diseases. Its research is aimed at the treatment of human disease indications, particularly influenza, using natural human interferon alpha that is administered in a proprietary low dose oral form. It currently owns or licenses five issued patents related to the low-dose oral delivery of interferon and it owns one issued patent on its dietary supplement, Maxisal. The Company has completed more than 100 pre-clinical (animal) and human studies on the safety and efficacy of low-dose orally administered interferon.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018